Beyond Air (STU:48L) 5-Year Yield-on-Cost %: 0.00 (As of Aug. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:48L Beyond Air Inc STU:48L
25 GF Score
Price €68.40
GF Value €1,456.71
! 7 Warning Signs
View Full Analysis

What is Beyond Air 5-Year Yield-on-Cost %?

Beyond Air STU:48L 25 5-Year Yield-on-Cost % is 0.00 as of Aug. 06, 2026. GuruFocus rates STU:48L with a GF Score™ of 25/100 and a GF Value™ of €1,456.71. The stock has 7 warning signs investors should review. Among 317 Medical Devices & Instruments companies, Beyond Air ranks worse than 315457.1% on this metric.

Beyond Air's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Beyond Air's 5-Year Yield-on-Cost % or its related term are showing as below:



STU:48L's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.41
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Beyond Air  (STU:48L) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Beyond Air 5-Year Yield-on-Cost % Related Terms


STU:48L vs POAS, RMSL, LUDG: 5-Year Yield-on-Cost % Comparison

For the Medical Devices subindustry, Beyond Air's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beyond Air 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Beyond Air's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Beyond Air's 5-Year Yield-on-Cost % falls into.


STU:48L
25GF Score
Beyond Air Inc STU:48L
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beyond Air 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Beyond Air is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Beyond Air (STU:48L) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 06, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Beyond Air and its competitors. According to the industry distribution chart, Beyond Air ranks #999999 out of 317 companies in the Medical Devices & Instruments industry.
Is Beyond Air's 5-Year Yield-on-Cost % too high?
Beyond Air's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Beyond Air ranks #999999 out of 317 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Beyond Air has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Beyond Air's 5-Year Yield-on-Cost % compare to POAS and RMSL?
According to the Medical Devices & Instruments industry distribution chart, Beyond Air ranks #999999 out of 317 companies for 5-Year Yield-on-Cost %. This places Beyond Air in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.41, based on 317 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Beyond Air and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beyond Air's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beyond Air stock overvalued right now?
Beyond Air (STU:48L) has a current 5-Year Yield-on-Cost % of 0.00. The stock's GF Value™ is €1,456.71, compared to a current price of €68.40 — trading 95.3% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Beyond Air's overall GF Score™ is 25/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Beyond Air (STU:48L), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beyond Air (STU:48L) Overvalued in 2026?

Based on GuruFocus' analysis, Beyond Air stock appears to be undervalued. The current stock price of €68.40 is trading 95.3% below its estimated GF Value™ of €1,456.71.

Key valuation signals for STU:48L:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: €1,456.71 vs. price of €68.40 (95.3% below fair value)
  • GF Score™: 25/100 with 7 warning signs

No single metric tells the full story. See the STU:48L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Beyond Air Business Description

Other Exchanges XAIR:USA
Address 900 Stewart Avenue, Suite 301, Garden City, New York, NY, USA, 11530
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
25GF Score

Get the complete analysis for STU:48L

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€68.40
Price
€1,456.71
GF Value